Advertisement

Disease Modification Through Trophic Factor Delivery

  • Mari Savolainen
  • Dwaine Emerich
  • Jeffrey H. KordowerEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1780)

Abstract

Huntington’s disease (HD) is characterized by a significant loss of striatal neurons that project to the globus pallidus and substantia nigra, together with loss of cortical projection neurons in varying regions. Mutant huntingtin is suggested to drive the pathogenesis partially by downregulating corticostriatal brain-derived neurotrophic factor (BDNF) levels and signaling. Neurotrophic factors are endogenous peptides that promote the survival and maintenance of neurons. BDNF and other neurotrophic factors have shown neuroprotective benefits in various animal models of neurodegeneration, and are interesting candidates to protect the cell populations that are destined to die in HD. In an attempt to enhance the delivery of neurotrophic factors, several methods have been established to deliver long-term neurotrophic factor gene therapy to human target tissues. This chapter discusses two alternative approaches that have been shown to have potential to deliver neurotrophic factors as a neuroprotective gene therapy for HD. The methods are (1) ex vivo approach where encapsulated cells engineered to express neurotrophic factor are inserted into brain parenchyma or ventricle, and (2) in vivo viral vector therapy, in which viral vector is injected into desired brain area to express gene of interest in the host cells.

Keywords

Neurotrophic factors Glial-derived neurotrophic factor, GDNF Ciliary neurotrophic factor, CDNF Neurturin Gene therapy Adeno-associated viral vector, AAV Encapsulated cells 

Notes

Acknowledgments

Mari Savolainen is funded by The Finnish Cultural Foundation, The Finnish Parkinsons Foundation, and The Maud Kuistila Memorial Foundation.

References

  1. 1.
    Rubinsztein DC, Leggo J, Coles R et al (1996) Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats. Am J Hum Genet 59:16–22PubMedPubMedCentralGoogle Scholar
  2. 2.
    Vonsattel JP, Myers RH, Stevens TJ et al (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Glass M, Dragunow M, Faull RL (2000) The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience 97:505–519CrossRefPubMedGoogle Scholar
  4. 4.
    Han I, You Y, Kordower JH et al (2010) Differential vulnerability of neurons in Huntington’s disease: the role of cell type-specific features. J Neurochem 113:1073–1091PubMedPubMedCentralGoogle Scholar
  5. 5.
    Tippett LJ, Waldvogel HJ, Thomas S et al (2007) Striosomes and mood dysfunction in Huntington’s disease. Brain 130:206–221CrossRefPubMedGoogle Scholar
  6. 6.
    Reiner A, Albin RL, Anderson KD et al (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 85:5733–5737CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mehrabi NF, Waldvogel HJ, Tippett LJ et al (2016) Symptom heterogeneity in Huntington’s disease correlates with neuronal degeneration in the cerebral cortex. Neurobiol Dis 96:67–74CrossRefPubMedGoogle Scholar
  8. 8.
    Thu DCV, Oorschot DE, Tippett LJ et al (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington’s disease. Brain 133:1094–1110CrossRefPubMedGoogle Scholar
  9. 9.
    Macdonald V, Halliday G (2002) Pyramidal cell loss in motor cortices in Huntington’s disease. Neurobiol Dis 10:378–386CrossRefPubMedGoogle Scholar
  10. 10.
    Rosas HD, Salat DH, Lee SY et al (2008) Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain 131:1057–1068CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Walker FO (2007) Huntington’s disease. Lancet 369:218–228CrossRefPubMedGoogle Scholar
  12. 12.
    Gunawardena S, Goldstein LSB (2005) Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol 62:46–51CrossRefPubMedGoogle Scholar
  13. 13.
    Martinez-Vicente M, Talloczy Z, Wong E et al (2010) Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease. Nat Neurosci 13:567–576CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    DiFiglia M, Sapp E, Chase KO et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990–1993CrossRefPubMedGoogle Scholar
  15. 15.
    Altar AC, Cai N, Bliven T et al (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389:856–860CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 293:493–498CrossRefPubMedGoogle Scholar
  17. 17.
    Zuccato C, Marullo M, Conforti P (2008) Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington’s disease. Brain Pathol 18:225–238Google Scholar
  18. 18.
    Altar CA, Siuciak JA, Wright P et al (1994) In situ hybridization of trkB and trkC receptor mRNA in rat forebrain and association with high-affinity binding of [125I]BDNF, [125I]NT-4/5 and [125I]NT-3. Eur J Neurosci 6:1389–1405CrossRefPubMedGoogle Scholar
  19. 19.
    Ginés S, Bosch M, Marco S et al (2006) Reduced expression of the TrkB receptor in Huntington’s disease mouse models and in human brain. Eur J Neurosci 23:649–658CrossRefPubMedGoogle Scholar
  20. 20.
    Plotkin JL, Day M, Peterson JD et al (2014) Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington’s disease. Neuron 83:178–188CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Brito V, Puigdellívol M, Giralt A et al (2013) Imbalance of p75(NTR)/TrkB protein expression in Huntington’s disease: implication for neuroprotective therapies. Cell Death Dis 4:e595CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lu B, Pang PT, Woo NH (2005) The yin and yang of neurotrophin action. Nat Rev Neurosci 6:603–614CrossRefPubMedGoogle Scholar
  23. 23.
    Brito V, Giralt A, Enriquez-Barreto L et al (2014) Neurotrophin receptor p75(NTR) mediates Huntington’s disease-associated synaptic and memory dysfunction. J Clin Invest 124:4411–4428CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Dallner C, Woods AG, Deller T et al (2002) CNTF and CNTF receptor alpha are constitutively expressed by astrocytes in the mouse brain. Glia 37:374–378CrossRefPubMedGoogle Scholar
  25. 25.
    Seidel JL, Faideau M, Aiba I et al (2015) Ciliary neurotrophic factor (CNTF) activation of astrocytes decreases spreading depolarization susceptibility and increases potassium clearance. Glia 63:91–103CrossRefPubMedGoogle Scholar
  26. 26.
    Wang X, Zheng H, Liu C et al (2008) Ciliary neurotrophic factor-treated astrocyte conditioned medium regulates the L-type calcium channel activity in rat cortical neurons. Neurochem Res 33:826–832CrossRefPubMedGoogle Scholar
  27. 27.
    Escartin C, Pierre K, Colin A et al (2007) Activation of astrocytes by CNTF induces metabolic plasticity and increases resistance to metabolic insults. J Neurosci 27:7094–7104CrossRefPubMedGoogle Scholar
  28. 28.
    Emerich DF, Winn SR, Hantraye PM et al (1997) Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington’s disease. Nature 386:395–399CrossRefPubMedGoogle Scholar
  29. 29.
    Mittoux V, Joseph JM, Conde F et al (2000) Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington’s disease. Hum Gene Ther 11:1177–1187CrossRefPubMedGoogle Scholar
  30. 30.
    Régulier E, Pereira de Almeida L et al (2002) Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington’s disease. Hum Gene Ther 13:1981–1990CrossRefPubMedGoogle Scholar
  31. 31.
    Bachoud-Lévi AC, Déglon N, Nguyen JP et al (2000) Neuroprotective gene therapy for Huntington’s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 11:1723–1729CrossRefPubMedGoogle Scholar
  32. 32.
    Bloch J, Bachoud-Lévi AC, Déglon N et al (2004) Neuroprotective gene therapy for Huntington’s disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 15:968–975CrossRefPubMedGoogle Scholar
  33. 33.
    Burazin TC, Gundlach AL (1999) Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum. Brain Res Mol Brain Res 73:151–171CrossRefPubMedGoogle Scholar
  34. 34.
    Lin LF, Doherty DH, Lile JD et al (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130–1132CrossRefPubMedGoogle Scholar
  35. 35.
    Kotzbauer PT, Lampe PA, Heuckeroth RO et al (1996) Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384:467–470CrossRefPubMedGoogle Scholar
  36. 36.
    Hidalgo-Figueroa M, Bonilla S, Gutiérrez F et al (2012) GDNF is predominantly expressed in the PV+ neostriatal interneuronal ensemble in normal mouse and after injury of the nigrostriatal pathway. J Neurosci 32:864–872CrossRefPubMedGoogle Scholar
  37. 37.
    Araujo DM, Hilt DC (1997) Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington’s disease. Neuroscience 81:1099–1110CrossRefPubMedGoogle Scholar
  38. 38.
    Araujo DM, Hilt DC (1998) Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid. Neuroscience 82:117–127CrossRefPubMedGoogle Scholar
  39. 39.
    Anderson KD, Panayotatos N, Corcoran TL et al (1996) Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc Natl Acad Sci U S A 93:7346–7351CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Volpe BT, Wildmann J, Altar CA (1998) Brain-derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal-pallidal lesions. Neuroscience 83:741–748CrossRefPubMedGoogle Scholar
  41. 41.
    Canals JM, Pineda JR, Torres-Peraza JF et al (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington’s disease. J Neurosci 24:7727–7739CrossRefPubMedGoogle Scholar
  42. 42.
    Griffioen KJ, Wan R, Brown TR et al (2012) Aberrant heart rate and brainstem brain-derived neurotrophic factor (BDNF) signaling in a mouse model of Huntington’s disease. Neurobiol Aging 33:1481.e1–1481.e5CrossRefGoogle Scholar
  43. 43.
    Giampà C, Montagna E, Dato C et al (2013) Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington’s disease. PLoS One 8:e64037CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Emerich DF, Lindner MD, Winn SR et al (1996) Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington’s disease. J Neurosci 16:5168–5181CrossRefPubMedGoogle Scholar
  45. 45.
    Emerich DF, Bruhn S, Chu Y, Kordower JH (1998) Cellular delivery of CNTF but not NT-4/5 prevents degeneration of striatal neurons in a rodent model of Huntington’s disease. Cell Transplant 7:213–225PubMedGoogle Scholar
  46. 46.
    Popovic N, Maingay M, Kirik D, Brundin P (2005) Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp Neurol 193:65–74CrossRefPubMedGoogle Scholar
  47. 47.
    Denovan-Wright EM, Attis M, Rodriguez-Lebron E, Mandel RJ (2008) Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice. J Neurosci Res 86:1748–1757CrossRefPubMedGoogle Scholar
  48. 48.
    McBride JL, Ramaswamy S, Gasmi M et al (2006) Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington’s disease. Proc Natl Acad Sci U S A 103:9345–9350CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Ramaswamy S, McBride JL, Han I et al (2009) Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington’s disease. Neurobiol Dis 34:40–50CrossRefPubMedGoogle Scholar
  50. 50.
    Zala D, Bensadoun J-C, Pereira de Almeida L et al (2004) Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington’s disease transgenic mice. Exp Neurol 185:26–35CrossRefPubMedGoogle Scholar
  51. 51.
    McBride JL, During MJ, Wuu J et al (2003) Structural and functional neuroprotection in a rat model of Huntington’s disease by viral gene transfer of GDNF. Exp Neurol 181:213–223CrossRefPubMedGoogle Scholar
  52. 52.
    Ramaswamy S, McBride JL, Herzog CD et al (2007) Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington’s disease. Neurobiol Dis 26:375–384CrossRefPubMedGoogle Scholar
  53. 53.
    Mittoux V, Ouary S, Monville C et al (2002) Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J Neurosci 22:4478–4486CrossRefPubMedGoogle Scholar
  54. 54.
    Kells AP, Fong DM, Dragunow M et al (2004) AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 9:682–688CrossRefPubMedGoogle Scholar
  55. 55.
    Kells AP, Henry RA, Connor B (2008) AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment. Gene Ther 15:966–977CrossRefPubMedGoogle Scholar
  56. 56.
    Dionne KE, Cain BM, Li RH et al (1996) Transport characterization of membranes for immunoisolation. Biomaterials 17:257–266CrossRefPubMedGoogle Scholar
  57. 57.
    Aebischer P, Tresco PA, Winn SR et al (1991) Long-term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line. Exp Neurol 111:269–275CrossRefPubMedGoogle Scholar
  58. 58.
    Lindner MD, Plone MA, Frydel B et al (1997) Intraventricular encapsulated calf adrenal chromaffin cells: viable for at least 500 days in vivo without detectable adverse effects on behavioral/cognitive function or host immune sensitization in rats. Restor Neurol Neurosci 11:21–35PubMedGoogle Scholar
  59. 59.
    Emerich DF, Orive G, Thanos C et al (2014) Encapsulated cell therapy for neurodegenerative diseases: from promise to product. Adv Drug Deliv Rev 67–68:131–141CrossRefPubMedGoogle Scholar
  60. 60.
    Fjord-Larsen L, Kusk P, Tornøe J et al (2010) Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the Göttingen minipig basal forebrain. Mol Ther 18:2164–2172CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Wahlberg LU, Lind G, Almqvist PM et al (2012) Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J Neurosurg 117:340–347CrossRefPubMedGoogle Scholar
  62. 62.
    Fjord-Larsen L, Kusk P, Emerich DF et al (2012) Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer. Gene Ther 19:1010–1017CrossRefPubMedGoogle Scholar
  63. 63.
    Gray SJ, Woodard KT, Samulski RJ (2010) Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv 1:517–534CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Choi VW, McCarty DM, Samulski RJ (2005) AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 5:299–310CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Hadaczek P, Eberling JL, Pivirotto P et al (2010) Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 18:1458–1461CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Kordower JH, Emborg ME, Bloch J et al (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 290:767–773CrossRefPubMedGoogle Scholar
  67. 67.
    Thomas CE, Birkett D, Anozie I et al (2001) Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther 3:36–46CrossRefPubMedGoogle Scholar
  68. 68.
    Aschauer DF, Kreuz S, Rumpel S (2013) Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One 8:e76310CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Morfini GA, You Y-M, Pollema SL et al (2009) Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci 12:864–871CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Stokin GB, Lillo C, Falzone TL et al (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science 307:1282–1288CrossRefPubMedGoogle Scholar
  71. 71.
    Chu Y, Morfini GA, Langhamer LB et al (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease. Brain 135:2058–2073CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Szebenyi G, Morfini GA, Babcock A et al (2003) Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40:41–52CrossRefPubMedGoogle Scholar
  73. 73.
    Bartus RT, Herzog CD, Chu Y et al (2011) Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson’s disease and nonhuman primate brains. Mov Disord 26:27–36CrossRefPubMedGoogle Scholar
  74. 74.
    Marks WJ Jr, Bartus RT, Siffert J et al (2010) Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9:1164–1172CrossRefPubMedGoogle Scholar
  75. 75.
    Olanow WC, Bartus RT, Baumann TL et al (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 78:248–257CrossRefGoogle Scholar
  76. 76.
    Taymans J-M, Vandenberghe LH, Haute CVD et al (2007) Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 18:195–206CrossRefPubMedGoogle Scholar
  77. 77.
    Burger C, Gorbatyuk OS, Velardo MJ et al (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302–317CrossRefPubMedGoogle Scholar
  78. 78.
    Markakis EA, Vives KP, Bober J et al (2010) Comparative transduction efficiency of AAV vector serotypes 1–6 in the substantia nigra and striatum of the primate brain. Mol Ther 18:588–593CrossRefPubMedGoogle Scholar
  79. 79.
    Dodiya HB, Björklund T, Stansell J et al (2010) Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 18:579–587CrossRefPubMedGoogle Scholar
  80. 80.
    Hadaczek P, Stanek L, Ciesielska A et al (2016) Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington’s disease. Mol Ther Methods Clin Dev 3:16037CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Li W, Asokan A, Wu Z et al (2008) Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 16:1252–1260CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Erles K, Sebökovà P, Schlehofer JR (1999) Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 59:406–411CrossRefPubMedGoogle Scholar
  83. 83.
    Chirmule N, Propert K, Magosin S et al (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574–1583CrossRefPubMedGoogle Scholar
  84. 84.
    Peden CS, Burger C, Muzyczka N, Mandel RJ (2004) Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 78:6344–6359CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Gloaguen I, Costa P, Demartis A et al (1997) Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci U S A 94:6456–6461CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Kokoeva MV, Yin H, Flier JS (2005) Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 310:679–683CrossRefPubMedGoogle Scholar
  87. 87.
    Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493–506CrossRefPubMedGoogle Scholar
  88. 88.
    Marks WJ Jr, Baumann TL, Bartus RT (2016) Long-term safety of patients with Parkinson’s disease receiving rAAV2-neurturin (CERE-120) gene transfer. Hum Gene Ther 27:522–527CrossRefPubMedGoogle Scholar
  89. 89.
    Bartus RT, Johnson EM Jr (2017) Clinical tests of neurotrophic factors for human neurodegenerative diseases: Part 2. Where do we stand and where must we go next? Neurobiol Dis 97:169–178CrossRefPubMedGoogle Scholar
  90. 90.
    Yang S-H, Cheng P-H, Banta H et al (2008) Towards a transgenic model of Huntington’s disease in a non-human primate. Nature 453:921–924CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Chan AW, Xu Y, Jiang J et al (2014) A two years longitudinal study of a transgenic Huntington disease monkey. BMC Neurosci 15:36CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Chan AWS, Jiang J, Chen Y et al (2015) Progressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood. PLoS One 10:e0122335CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Mari Savolainen
    • 1
  • Dwaine Emerich
    • 2
  • Jeffrey H. Kordower
    • 1
    • 3
    Email author
  1. 1.Department of Neurological SciencesRush University Medical CenterChicagoUSA
  2. 2.NsGene, Inc.ProvidenceUSA
  3. 3.The Van Andel Research InstituteGrand RapidsUSA

Personalised recommendations